PRLD
Prelude Therapeutics Incorporated
NASDAQ · USHealthcareBiotechnology
$4.06-3.33%
Price as of Jul 20, 2026
PRLD financials
Prelude Therapeutics Incorporated financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $12.1M | $7.0M | $0.00 | $0.00 |
| Cost of revenue | $1.7M | $0.00 | $0.00 | $0.00 |
| Gross profit | $10.4M | $7.0M | $0.00 | $0.00 |
| Operating expenses | $115.0M | $146.7M | $132.3M | $123.5M |
| Operating income | -$104.6M | -$139.7M | -$132.3M | -$123.5M |
| Net income | -$99.5M | -$127.2M | -$121.8M | -$115.4M |
| EBITDA | -$97.8M | -$125.4M | -$120.7M | -$114.1M |
| Basic EPS | $-1.29 | $-1.68 | $-2.02 | $-2.27 |
| Diluted EPS | $-1.29 | $-1.68 | $-2.02 | $-2.27 |
| Balance sheet | ||||
| Cash & equivalents | $35.3M | $12.5M | $25.3M | $30.6M |
| Total assets | $141.3M | $175.5M | $277.7M | $220.5M |
| Total liabilities | $72.7M | $44.1M | $40.6M | $25.1M |
| Stockholders’ equity | $68.6M | $131.5M | $237.1M | $195.4M |
| Total debt | $17.8M | $18.0M | $16.9M | $1.8M |
| Net debt | -$17.5M | $5.6M | -$8.4M | -$28.8M |
| Cash flow | ||||
| Operating cash flow | -$56.3M | -$102.9M | -$107.1M | -$83.7M |
| Capital expenditure | -$67.0K | -$764.0K | -$3.5M | -$3.0M |
| Free cash flow | -$56.4M | -$103.7M | -$110.6M | -$86.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |